The ophthalmic prefilled injectables market is projected to grow from USD 1.8 billion in 2025 to USD 4.3 billion by 2035, at a CAGR of 9.3%. Biologic Anti-VEGF Agents will dominate with a 55.60% market share, while retinal vascular disorders will lead the indication segment with a 53.4% share.